natgillin/translations-raw huggingface dataset:
No special storage requirements prior to reconstitution.
Za shranjevanje pred. itucijo niso potrebna posebna navodila.
After dilution the infusion solution is stable for 24 hours at 2 °C – 8 °C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku)
Bondronat 6 mg concentrate for solution for infusion ibandronic acid I. V. use
Bondronat 6 mg koncentrat za raztopino za infundiranje ibandronska kislina i. v. uporaba
54 PACKAGE LEAFLET:
54 NAVODILO ZA UPORABO
What Bondronat is and what it is used for 2.
Kaj je zdravilo Bondronat in za kaj ga uporabljamo 2.
Before you use Bondronat 3.
Kaj morate vedeti, preden boste prejeli zdravilo Bondronat 3.
How to use Bondronat 4.
Kako uporabljati zdravilo Bondronat 4.
How to store Bondronat 6.
Možni neželeni učinki 5 Shranjevanje zdravila Bondronat 6.
WHAT BONDRONAT IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO BONDRONAT IN ZA KAJ GA UPORABLJAMO
The active substance of Bondronat, ibandronic acid, belongs to the group of medicines known as bisphosphonates.
Zdravilna učinkovina zdravila Bondronat, ibandronska kislina, spada v skupino zdravil, ki se imenujejo bisfosfonati.
It inhibits increased loss of calcium from the bones (bone resorption), thus normalising elevated serum calcium levels.
Zavira povečano izločanje kalcija iz kosti (resorpcija kosti) in s tem uravnava zvišane koncentracije kalcija v serumu.
It also prevents bone complications and fractures related to the spread of cancer cells into bone.
Preprečuje tudi zaplete pri kosteh in zlome, ki so povezani z razširitvijo rakavih celic v kosti.
Bondronat is indicated for:
Bondronat je indiciran za:
- Pathologically (abnormally) elevated serum calcium levels (hypercalcaemia) as a result of
- patološko (nenormalno) zvišane serumske koncentracije kalcija (hiperkalciemija) kot posledica
tumours
tumorjev,
- Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy
- preprečevanje dogodkov povezanih z okostjem (patološke frakture; zapleti, pri katerih je
BEFORE YOU USE BONDRONAT
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO BONDRONAT
During treatment your blood may be monitored to ensure that you are receiving the correct dose of Bondronat.
Med zdravljenjem vam bodo morda opravili pregled krvi, da bodo zagotovili pravilen odmerek zdravila Bondronat.
If you are under dental treatment or will undergo dental surgery, tell your dentist that you are being treated with Bondronat
Pred zdravljenjem bolezni ali operacijo zob povejte svojemu zobozdravniku, da se zdravite z zdravilom Bondronat.
Do not use Bondronat:
Ne uporabljajte zdravila Bondronat:
- if you are allergic (hypersensitive) to the active substance or any of the other ingredients of
- če ste alergični na (preobčutljivi za) zdravilno učinkovino ali katerokoli drugo sestavino
Bondronat.
zdravila Bondronat.
Take special care with Bondronat: if you know or believe that you may have:
Bodite posebno pozorni pri uporabi zdravila Bondronat
55
55 Če veste ali mislite, da:
- hypersensitivity to other bisphosphonates
- ste preobčutljivi za druge bisfosfonate,
- low blood calcium
- imate nizke koncentracije kalcija v krvi,
- other disturbances of mineral metabolism (such as vitamin D deficiency)
- imate druge motnje presnove mineralov (kot pomanjkanje vitamina D),
- severe kidney disease (renal insufficiency i. e. creatinine clearance < 30 ml/ min)
- imate hudo ledvično bolezen (ledvično insuficienco tj. kreatininski očistek < 30 ml/ min).
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Uporaba drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
No interaction was observed when ibandronic acid was administered concomitantly with tamoxifen, or melphalan/ prednisolone.
Pri sočasnem jemanju ibandronske kisline s tamoksifenom, melfalanom ali prednizolonom niso opazili medsebojnega delovanja.
Caution is advised when bisphosphonates are administered with aminoglycosides since both agents can lower serum calcium levels for prolonged periods.
Pri sočasnem jemanju bisfosfonatov z aminoglikozidi je potrebna previdnost, ker lahko oboji znižajo koncentracijo kalcija v serumu za dlje časa.
Caution should also be paid to the possible existence of simultaneous hypomagnesaemia (reduced magnesium levels).
Pozorni moramo biti tudi na možnost razvoja hipomagneziemije (znižano koncentracijo magnezija).
Pregnancy and breast-feeding You should not be given Bondronat if you are pregnant or if you are breast-feeding.
Nosečnost in dojenje Če ste noseči ali dojite, zdravila Bondronat ne smete jemati.
The effects of Bondronat on the ability to drive or to use machines has not been studied.
Vpliv na sposobnost upravljanja vozil in strojev Vplivov zdravila Bondronat na sposobnost upravljanja vozil in strojev niso proučevali.
HOW TO USE BONDRONAT
KAKO UPORABLJATI ZDRAVILO BONDRONAT
You will be given Bondronat as an infusion. Your doctor will determine how much Bondronat you will be given depending on your illness.
Glede na vašo bolezen bo vaš zdravnik določil, koliko zdravila Bondronat boste prejeli.
Your doctor may adjust your dose if you have kidney problems.
Če imate ledvične težave, bo zdravnik morda prilagodil odmerek.
Like all medicines, Bondronat can cause side effects although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Bondronat neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The side effects listed below were seen when Bondronat was given intravenously.
Spodaj našteti neželeni učinki so bili opaženi pri intravenskem dajanju zdravila Bondronat.
• Side effects described as very common were experienced in more than 1 in 10 patients. • Side effects described as common were experienced by up to 1 in 10 patients. • Side effects described as rare or very rare were experienced by fewer than 1 in 100 patients
• Neželeni učinki, opisani kot zelo pogosti, so se pojavili pri več kot 1 od 10 bolnikov. • Neželeni učinki, opisani kot pogosti, so se pojavili pri do 1 od 10 bolnikov. • Neželeni učinki, opisani kot redki ali zelo redki, so se pojavili pri manj kot 1 od 100 bolnikov.
A very common side effect is a rise in body temperature.
Zelo pogost neželeni učinek je povišanje telesne temperature.
Common side effects are flu-like symptoms (including fever, chills, bone pain and aching muscles), tiredness, diarrhea, indigestion, vomiting, headache, dizziness, gastrointestinal pain, sore throat, and swelling of the lower limbs.
Pogosti neželeni učinki so gripi podobni simptomi (vključujoč vročino, mrzlico, bolečino v kosteh in mišicah), utrujenost, driska, slaba prebava, bruhanje, glavobol, vrtoglavica, gastrointestinalna bolečina, vneto grlo in otekanje spodnjih okončin.
These symptoms usually disappear within a couple of hours/ days.
Ti simptomi običajno izginejo v nekaj urah oz. dneh.
Less commonly patients have reported infections, strange taste, cataracts, bundle branch block, tooth disorder, skin problems, aching joints, arthritis, and thirst.
Manj pogosto so bolniki poročali o okužbah, nenavadnem okusu, očesnih mrenah, kračnem bloku, bolezni zob, kožnih težavah, bolečih sklepih, artritisu in žeji.
In rare cases, patients have reported the following: gastroenteritis, oral thrush, vaginitis, benign skin growth, sleep disturbance, anxiety, affect lability, memory loss, numbness round the mouth (paraesthesia circumoral), hyperaesthesia, hypertonia, nerve root lesion, neuralgia, migraine, cerebrovascular disorder, parosmia, deafness, heart and circulatory problems (including palpitations, myocardial ischaemia, hypertension, varicose veins), lymphoedema, lung oedema, stridor, gastritis,
V redkih primerih so bolniki poročali naslednje: gastroenteritis, ustni oprh, vaginitis, benigna rast kože, motnje spanja, zaskrbljenost, vpliv na čustveno labilnost, izguba spomina, mravljinčenje okoli
56 cheilitis, difficulty swallowing (dysphagia), mouth ulceration, gall stones cholelithiasis, rash, hair loss, cystitis, renal cyst, urinary retention, pelvic pain, injection site pain, weight loss, and hypothermia.
56 ust (parestezija okoli ust), hiperastezija, hipertonija, lezija živčnih korenov, nevralgija, migrena, cerebrovaskularna bolezen, parozmija, gluhost, težave s srcem in obtočili (vključno s palpitacijami, srčnomišična ishemija, povišan krvni tlak, krčne žile), limfni edem, pljučni edem, stridor, gastritis, heilitis, težko požiranje (disfagija), ulceracija ust, žolčni kamni (holelitiaza), osip, izguba las, vnetje mehurja, ledvična cista, zastajanje seča, bolečina v medenici, bolečina na mestu injiciranja, izguba telesne mase in hipotermija.
Bondronat may also cause changes in laboratory tests carried out by your doctor, these include; low calcium (metal), low phosphate (mineral), raised liver enzyme and raised creatinine, parathyroid disorder (hormone) in the blood, low hemoglobin (and rarely blood dyscrasia).
Zdravilo Bondronat lahko povzroči tudi spremembe v laboratorijskih testih, ki vam jih odredi vaš zdravnik: nizek kalcij (kovina), nizek fosfat (mineral), povišan jetrni encim in povišan kreatinin, motnja obščitnice (hormon v krvi), nizek hemoglobin in redko diskrazija krvi.
Very rarely, patients have had an allergic reaction to Bondronat which may cause wheezing and breathlessness or skin rashes.
Zelo redko so bolniki imeli alergijske reakcije na zdravilo Bondronat, ki lahko povzročijo sopenje in zasoplost ali kožne izpuščaje.
HOW TO STORE BONDRONAT
SHRANJEVANJE ZDRAVILA BONDRONAT
The shelf-life of Bondronat 2 mg is 5 years.
Rok uporabnosti zdravila Bondronat 2 mg je 5 let.
After dilution the infusion solution is stable for 24 hours at 2-8 °C(in a refrigerator).
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku).
Do not use Bondronat after the expiry date which is stated on the folding box and on the label.
Zdravila Bondronat ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki.
Do not use Bondronat if you notice that the solution is not clear or contains particles.
Ne uporabljajte zdravila Bondronat, če opazite, da raztopina ni bistra ali vsebuje vidne delce.
Unused solution should be discarded.
Neuporabljeno raztopino je treba zavreči.
- One vial with 2 ml concentrate for solution for infusion contains2 mg ibandronic acid (as
- Ena viala z 2 ml koncentrata za raztopino za infundiranje vsebuje 2 mg ibandronske kisline (kot
2.25 mg ibandronic acid, monosodium salt, monohydrate).
2, 25 mg ibandronske kisline v obliki monohidrata natrijeve soli.
- The other ingredients are sodium chloride, acetic acid, sodium acetate and water for injections.
- Pomožne snovi so natrijev klorid, ocetna kislina, natrijev acetat in voda za injekcije.
Bondronat is supplied as packs containing 1 vial (2 ml type I glass vial).
Zdravilo Bondronat je na voljo v pakiranju po 1 vialo (2 ml viala iz stekla tipa I).
Manufacturer Roche Diagnostics GmbH Sandhofer Strasse 116 D-68305 Mannheim Germany
57 Roche Diagnostics GmbH Sandhofer Strasse 116 D- 68305 Mannheim Nemčija
Kύπρος Γ .Α .Στα µάτης & Σια Λτδ.
58 Kύπρος Γ. Α. Σταµάτης & Σια Λτδ.
------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only
------------------------------------------------------------------------------------------------------------------------------ Naslednje informacije so namenjene samo zdravstvenemu osebju
Prevention of Skeletal Events in Patients with Breast Cancer and Bone Metastases The recommended dose for prevention of skeletal events in patients with breast cancer and bone metastases is 6 mg intravenously given every 3-4 weeks.
Odmerjanje: preprečevanje dogodkov, povezanih z okostjem pri bolnikih z rakom dojke in metastazami v kosteh Priporočeni odmerek za preprečevanje dogodkov, povezanih z okostjem pri bolnikih z rakom dojke in metastazami v kosteh je 6 mg intravensko danih vsake 3 do 4 tedne.
CLcr < 50 < 30
2 mg / 1 ura
2 mg
500 ml
6 mg / 1 hour / 1 hour
dajanje
500 ml 500 ml
vsake 3 do 4 tedne
Tumour-induced Hypercalcemia Bondronat is usually administered in a hospital setting.
Odmerjanje: tumorsko povzročena hiperkalciemija Dajanje zdravila Bondronat običajno poteka v bolnišnici.
Prior to treatment with Bondronat the patient should be adequately rehydrated with 9 mg/ ml (0.9%) sodium chloride.
Pred začetkom zdravljenja z zdravilom Bondronat je potrebna zadostna rehidracija bolnika z natrijevim kloridom 9 mg/ ml (0, 9%).
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* ≥ 3 mmol/ l or ≥ 12 mg/ dl) 4 mg will be an adequate single dosage.
Pri večini bolnikov s hudo hiperkalciemijo (korigirani kalcij v serumu * ≥ 3 mmol/ l ali ≥ 12 mg/ dl) zadošča enkratni odmerek 4 mg.
59
59 * Opomba: koncentracije korigiranega kalcija v serumu izračunamo po naslednjih formulah:
Serum calcium (mmol/ l) - [0.02 x albumin (g/ l)] + 0.8 or
koncentracija kalcija v serumu (mmol/ l) – [0, 02 x albumin (g/ l)] + 0, 8 ali
Albumin-corrected Serum calcium (mg/ dl)
korigirani kalcij v serumu (mg/ dl)
Serum calcium (mg/ dl) + 0.8 x [4 - albumin (g/ dl)]
koncentracija kalcija v serumu (mg/ dl) + 0, 8 x [4 – albumin (g/ dl)]
The median time to relapse (reincrease of serum albumin corrected serum calcium above 3 mmol/ l) was 18-19 days for the 2 mg and 4 mg doses.
Mediana časa do relapsa (ponovnega zvišanja korigiranega kalcija v serumu nad 3 mmol/ l) je bila 18 do 19 dni za 2 mg in 4 mg odmerke.
For this purpose the contents of the vial are to be used as follows:
Vsebino viale uporabimo, kot sledi:
• Hypercalcaemia - added to 500 ml isotonic sodium chloride solution or 500 ml 5% dextrose solution and infused over 1-2 hours. • Prevention of Skeletal Events - added to 100 ml isotonic sodium chloride solution or 100 ml 5% dextrose solution and infused over at least 15 minutes.
• hiperkalciemija - dodamo k 500 ml izotonične raztopine natrijevega klorida ali k 500 ml 5 -% raztopine glukoze in infundiramo 1 do 2 uri. • preprečevanje z okostjem povezanih dogodkov - dodamo k 100 ml izotonične raztopine natrijevega klorida ali k 100 ml 5 -% raztopine glukoze in infundiramo vsaj 15 minut.
See also dosage section above for patients with renal impairment.
Glejte tudi zgornje poglavje o odmerjanju pri bolnikih z ledvično okvaro.
In order to avoid potential incompatibilities, Bondronat concentrate for solution for infusion should only be mixed with isotonic sodium chloride solution or with 5% dextrose solution.
Da se izognemo možnim nezdružljivostim, lahko koncentrat za raztopino za infundiranje Bondronat razredčimo le z izotonično raztopino natrijevega klorida ali 5 -% raztopino glukoze.
It is recommended that the product once diluted be used immediately (see point 5 of this leaflet “ HOW TO STORE BONDRONAT”).
SHRANJEVANJE ZDRAVILA BONDRONAT).
As the inadvertent intra-arterial administration of preparations not expressly recommended for this purpose as well as paravenous administration can lead to tissue damage, care must be taken to ensure that Bondronat concentrate for solution for infusion is administered intravenously.
Koncentrat za raztopino za infundiranje Bondronat je treba dajati intravensko.
Frequency of administration For treatment of tumour induced hypercalcemia, Bondronat concentrate for solution for infusion is generally given as a single infusion.
Pogostnost dajanja Za zdravljenje tumorsko povzročene hiperkalciemije običajno dajemo koncentrat za raztopino za infundiranje Bondronat kot enkratno infuzijo.
For the prevention of skeletal events in patients with breast cancer and bone metastases, the Bondronat infusion is repeated at 3-4 week intervals.
Za preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh infuzijo zdravila Bondronat ponovimo v 3 - do 4- tedenskih intervalih.
Duration of treatment A limited number of patients (50 patients) have received a second infusion for hypercalcaemia.
Trajanje zdravljenja Omejeno število bolnikov (50 bolnikov) je prejelo drugo infuzijo zaradi hiperkalciemije.
For patients with breast cancer and bone metastases, Bondronat infusion should be administered every 3-4 weeks.
Bolnikom z rakom dojke in metastazami v kosteh morajo prejeti infuzijo zdravila Bondronat vsake 3 do 4 tedne.
Overdose Up to now there is no experience of acute poisoning with Bondronat concentrate for solution for infusion.
60 Ni poročil o primerih akutnega prevelikega odmerjanja s koncentratom za raztopino za infundiranje Bondronat.
60 Clinically relevant hypocalcaemia (very low serum calcium levels) should be corrected by intravenous administration of calcium gluconate.
Klinično pomembno hipokalciemijo (zelo nizke koncentracije kalcija v serumu) je treba popraviti z intravenskim dajanjem kalcijevega glukonata.
61 PACKAGE LEAFLET:
61 NAVODILO ZA UPORABO
Read all of this leaflet carefully before you start taking this medicine.
Pred uporabo natančno preberite navodilo.
2.
Kaj je zdravilo Bondronat in za kaj ga uporabljamo 2.
3.
Kaj morate vedeti, preden boste vzeli zdravilo Bondronat 3.
4.
Kako jemati zdravilo Bondronat 4.
6.
Možni neželeni učinki 5 Shranjevanje zdravila Bondronat 6.
It inhibits increased loss of calcium from the bones (bone resorption), and prevents bone complications and fractures related to the spread of cancer cells into bone.
Zavira povečano izločanje kalcija iz kosti (resorpcija kosti) in preprečuje zaplete pri kosteh in zlome, ki so povezani z razširitvijo rakavih celic v kosti.
Bondronat tablets are indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
Tablete Bondronat so indicirane za preprečevanje z okostjem povezanih dogodkov (patološke frakture; zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in z metastazami v kosteh.
BEFORE YOU TAKE BONDRONAT
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO BONDRONAT
- if you are allergic (hypersensitive) to ibandronic acid or any of the other ingredients
- če ste alergični na (preobčutljivi za) ibandronsko kislino ali katerokoli sestavino zdravila
Take special care with Bondronat: if you know or believe that you may have:
Bodite posebno pozorni pri jemanju zdravila Bondronat Če veste ali mislite, da:
- severe kidney disease (renal insufficiency i. e. creatinine clearance < 30 mL/ min)
- imate hudo ledvično bolezen (ledvično insuficienco tj. kreatininski očistek < 30 ml/ min)
62
62 ali če
- you have had problems in the past with your oesophagus (the tube that connects your mouth to
- ste v preteklosti imeli težave s požiralnikom (cevjo, ki povezuje usta z želodcem),
- you become aware of any signs or symptoms suggesting a possible reaction of the oesophagus
- opazite znake ali simptome, ki kažejo na možno reakcijo požiralnika (kar lahko vključuje
(this may include: pain in the chest, heartburn, pain after swallowing drink and / or food).
bolečino v prsih, zgago, bolečino pri požiranju pijače ali hrane).
If this is the case, you should speak to your doctor without delay.
V tem primeru se takoj pogovorite s svojim zdravnikom.
- you are also taking non-steroidal anti-inflammatory drugs (NSAIDs), since both types of
- jemljete nesteroidna protivnetna zdravila (NSAID), ker lahko obe vrsti zdravil (NSAID in
medicinal products (NSAIDs and bisphosphonates) may cause irritation to the stomach and intestine.
bisfosfonati) povzročita draženje želodca in črevesja,
- You suffer from galactose intolerance, the Lapp lactase deficiency or have problems with
- imate intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali težave z
glucose-galactose absorption
absorpcijo glukoze in galaktoze.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, or are taking supplements containing calcium, magnesium, iron or aluminium.
Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta ali če jemljete dodatke, ki vsebujejo kalcij, magnezij, železo ali aluminij.
When administered with H2-antagonists or other drugs that increase gastric pH Bondronat absorption may be slightly increased but no dose adjustment is needed.
Pri sočasnem jemanju zdravila Bondronat s H2- antagonisti in drugimi zdravili, ki povečajo želodčni pH, je lahko absorpcija zdravila Bondronat rahlo povečana, vendar prilagajanje odmerkov ni potrebno.
Caution is advised when bisphosphonates are administered with aminoglycosides since both agents can lower serum calcium levels for prolonged periods.
Pri sočasnem jemanju bisfosfonatov z aminoglikozidi je potrebna previdnost, ker lahko obe učinkovini znižata koncentracijo kalcija v serumu za dlje časa.
Caution should also be paid to the possible existence of simultaneous hypomagnesaemia (reduced magnesium levels).
Pozorni moramo biti tudi na možnost razvoja hipomagneziemije (znižane koncentracije magnezija).
After taking your Bondronat tablet, wait at least 30 minutes before taking any other medication of the day, including indigestion tablets/ medicine, calcium supplements and vitamins.
Ko vzamete tableto Bondronat, počakajte vsaj 30 minut, preden ta dan vzamete drugo zdravilo, vključno s tabletami ali zdravili za slabo prebavo, kalcijevimi dodatki in vitamini.
Your Bondronat tablets should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day.
Jemanje zdravila Bondronat skupaj s hrano in pijačo Tablete Bondronat morate vzeti po postu prek noči (najmanj 6 ur) in pred prvo hrano ali pijačo v dnevu.
Medications and supplements (including calcium) should similarly be avoided prior to taking Bondronat tablets.
Prav tako se pred jemanjem tablet Bondronat izogibajte zdravilom in dodatkom (vključno s kalcijem).
Fasting, including avoiding other medication and supplements should be continued for at least 30 minutes after taking the tablet.
Ko vzamete tableto, počakajte najmanj 30 minut, preden zaužijete hrano, pijačo ali druga zdravila in dodatke.
Plain water may be taken at any time during the course of Bondronat treatment.
Med zdravljenjem z zdravilom Bondronat lahko pijete navadno pitno vodo (nemineralno) kadarkoli.
You should not take Bondronat if you are pregnant or if you are breast-feeding.
Nosečnost in dojenje Če ste noseči ali dojite, zdravila Bondronat ne smete jemati.
Important information about some of the ingredients of Bondronat Bondronat tablets contain lactose.
Pomembna informacija o nekaterih sestavinah zdravila Bondronat Tablete zdravila Bondronat vsebujejo laktozo.
HOW TO TAKE BONDRONAT
KAKO JEMATI ZDRAVILO BONDRONAT
Always take Bondronat exactly as your doctor has told you.
Pri jemanju zdravila Bondronat natančno upoštevajte zdravnikova navodila.
The usual dose of Bondronat is one tablet per day.
Običajen odmerek zdravila Bondronat je ena tableta na dan.
If you have severe kidney problems, your doctor may reduce your dose to one tablet per week.
Če imate hudo ledvično bolezen, vam bo morda vaš zdravnik odmerek zmanjšal na eno tableto na teden.
To reduce possible irritation, it is important that you follow the instructions below:
Pomembno je, da se držite spodnjih navodil za zmanjšanje možnega draženja:
- BEFORE taking your first food, drink or other medicinal products of the day, take your
- PREDEN zaužijete prvo hrano, pijačo ali druga zdravila v dnevu, vzemite tableto Bondronat s
Bondronat tablet with a full glass of plain water only (about 200 mL).
polnim kozarcem navadne pitne vode (približno 200 ml).
Do not take your tablet with any drink other than plain water
Svojo tableto lahko vzamete le z navadno pitno vodo (nemineralno), z drugimi pijačami pa ne.
- Do not chew, suck or allow the tablet to dissolve in your mouth.
- Tablet ne žvečite, sesajte ali jih raztapljajte v ustih.
- After taking your Bondronat tablet, wait at least 30 minutes before taking your first food,
- Ko vzamete tableto Bondronat, počakajte vsaj 30 minut, preden zaužijete prvo hrano, pijačo ali